About Aevi Genomic Medicine
Aevi Genomic Medicine is a company based in Wayne (United States) founded in 2001 was acquired by Cerecor in December 2019. Aevi Genomic Medicine has raised $28.43 million across 12 funding rounds from investors including Children's Hospital of Philadelphia, Cerecor and Alta Partners. The company has 3 employees as of September 30, 2021. Aevi Genomic Medicine operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
- Headquarter Wayne, United States
- Employees 3 as on 30 Sep, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aevi Genomic Medicine, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$30.78 M (USD)11as on Dec 31, 2018
-
EBITDA
-$30.96 M (USD)11as on Dec 31, 2018
-
Total Equity Funding
$28.43 M (USD)
in 12 rounds
-
Latest Funding Round
$28 M (USD), Post-IPO
Aug 10, 2017
-
Investors
Children's Hospital of Philadelphia
& 4 more
-
Employee Count
3
as on Sep 30, 2021
-
Acquired by
Cerecor
(Dec 05, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aevi Genomic Medicine
Aevi Genomic Medicine has successfully raised a total of $28.43M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aevi Genomic Medicine
Aevi Genomic Medicine has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Children's Hospital of Philadelphia, Cerecor and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
VC firm investing in Western Europe, the US and Israel
|
Locked | Locked | Locked |
Investor details for Aevi Genomic Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aevi Genomic Medicine
Investment portfolio details for Aevi Genomic Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aevi Genomic Medicine
Detailed financials for Aevi Genomic Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aevi Genomic Medicine Comparisons
Peer comparison for Aevi Genomic Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aevi Genomic Medicine
Aevi Genomic Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
Detailed competitors of Aevi Genomic Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aevi Genomic Medicine
Complete news archive for Aevi Genomic Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aevi Genomic Medicine
Aevi Genomic Medicine was founded in 2001.
Aevi Genomic Medicine is headquartered in Wayne, United States.
Mike Cola is the current CEO of Aevi Genomic Medicine.
Aevi Genomic Medicine is a funded company, having raised a total of $28.43M across 12 funding rounds to date.
As of Sep 30, 2021, the latest employee count at Aevi Genomic Medicine is 3.
Aevi Genomic Medicine was founded in 2001 and is based in Wayne, United States. Operations center on the creation of treatments for pediatric-onset rare diseases, with emphasis on neurology and hematology sectors. The pipeline encompasses AEVI-001, a small molecule addressing metabotropic glutamate receptor mutations for ADHD and 22q deletion syndrome in Phase 1 and 2 trials, alongside AEVI-002, an anti-LIGHT monoclonal antibody for inflammatory bowel disease in Phase 1.
Aevi Genomic Medicine's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Aevi Genomic Medicine has 5 investors. Key investors include Children's Hospital of Philadelphia, Cerecor, Alta Partners, Koor Industries, and Alta Berkeley.